Filtered By:
Condition: Atrial Fibrillation
Management: Economics
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches
CONCLUSIONS: Screening for NVAF at ≥75 years of age could result in fewer NVAF-related strokes. NVAF screening is cost-effective and may be cost-saving depending on the program chosen.PMID:36757910 | DOI:10.1080/13696998.2023.2179210
Source: Journal of Medical Economics - February 9, 2023 Category: Health Management Authors: Shreeya Patel Thitima Kongnakorn Andreas Nikolaou Yassir Javaid Ruth Mokgokong Source Type: research
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
ConclusionsHCRU and most event-related costs were lower in patients initiating apixaban compared to other OACs. Apixaban may be cost-saving compared to VKAs, and significantly cheaper than other DOACs, although cost differences are limited.
Source: The European Journal of Health Economics - August 28, 2022 Category: Health Management Source Type: research
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis
CONCLUSION: Adherence improving interventions for NVAF patients on DOACs such as chronic disease co-management and patient education can be cost-saving and cost-effective, within a range of costs that appear reasonable to the Swedish healthcare system.PMID:35997241 | DOI:10.1080/13696998.2022.2116848
Source: Journal of Medical Economics - August 23, 2022 Category: Health Management Authors: C Blomstr öm Lundqvist S Sj älander L A Garcia Rodriguez Ö Åkerborg G Jin A Caleyachetty M Huelsebeck K Bowrin B Schaefer H Mahdessian L Hofmeister L Å Levin Source Type: research
The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis - Galvain T, Hill R, Donegan S, Lisboa P, Lip GYH, Czanner G.
BACKGROUND: Atrial fibrillation affects an estimated 33 million individuals worldwide and is a major cause of stroke, heart failure, and death. Anticoagulants substantially reduce the risk of stroke but are also associated with an increased risk of bleedin...
Source: SafetyLit - April 14, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
